ABC Arbitrage SA Has $6.55 Million Holdings in Fresenius Medical Care AG & Co. KGaA $FMS

ABC Arbitrage SA increased its position in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 18.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 229,375 shares of the company’s stock after purchasing an additional 35,314 shares during the period. ABC Arbitrage SA’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $6,553,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Cerity Partners LLC increased its holdings in Fresenius Medical Care AG & Co. KGaA by 22.4% in the 1st quarter. Cerity Partners LLC now owns 39,903 shares of the company’s stock valued at $994,000 after buying an additional 7,299 shares during the period. US Bancorp DE boosted its position in shares of Fresenius Medical Care AG & Co. KGaA by 225.5% during the 2nd quarter. US Bancorp DE now owns 75,660 shares of the company’s stock valued at $2,162,000 after acquiring an additional 52,418 shares in the last quarter. New York State Common Retirement Fund bought a new stake in Fresenius Medical Care AG & Co. KGaA in the first quarter valued at about $164,000. Advisors Asset Management Inc. raised its position in Fresenius Medical Care AG & Co. KGaA by 243.3% in the first quarter. Advisors Asset Management Inc. now owns 7,817 shares of the company’s stock worth $195,000 after purchasing an additional 5,540 shares in the last quarter. Finally, Kestra Private Wealth Services LLC bought a new position in Fresenius Medical Care AG & Co. KGaA during the first quarter worth about $286,000. 8.37% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on FMS shares. UBS Group lowered Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a research note on Wednesday, October 15th. Wall Street Zen lowered Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Bank of America cut Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research report on Wednesday, October 15th. Morgan Stanley reiterated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, August 12th. Finally, Weiss Ratings upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $30.00.

Fresenius Medical Care AG & Co. KGaA Trading Up 1.3%

Shares of NYSE FMS opened at $24.01 on Wednesday. Fresenius Medical Care AG & Co. KGaA has a 1-year low of $21.06 and a 1-year high of $30.46. The company has a market cap of $14.09 billion, a PE ratio of 19.68, a P/E/G ratio of 0.64 and a beta of 0.90. The company has a current ratio of 1.44, a quick ratio of 1.08 and a debt-to-equity ratio of 0.44. The company has a 50-day moving average of $25.94 and a two-hundred day moving average of $26.59.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.59 by $0.05. The business had revenue of $5.63 billion for the quarter, compared to analysts’ expectations of $4.72 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.39% and a return on equity of 6.75%. As a group, equities analysts expect that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current fiscal year.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.